Fresenius Medical Care AG
XMUN:FME
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Fresenius Medical Care AG
XMUN:FME
|
DE |
|
Holding Company ADMIE IPTO SA
LSE:0RQM
|
GR |
|
Investore Property Ltd
NZX:IPL
|
NZ |
|
F
|
Fiskars Oyj Abp
OTC:FKRAF
|
FI |
|
R
|
Rio Tinto PLC
DUS:RIO1
|
UK |
|
ITV PLC
LSE:ITV
|
UK |
|
B
|
Beforepay Group Ltd
ASX:B4P
|
AU |
|
UFP Technologies Inc
F:UFP
|
US |
|
C
|
Caterpillar Inc
DUS:CAT1
|
US |
|
Ascendis Pharma A/S
NASDAQ:ASND
|
DK |
|
C
|
Cintas Corp
DUS:CIT
|
US |
|
Tencent Holdings Ltd
HKEX:700
|
CN |
|
Schneider Electric SE
F:SNDB
|
FR |
|
Nexstar Media Group Inc
NASDAQ:NXST
|
US |
|
Air China Ltd
SSE:601111
|
CN |
|
Asmallworld AG
SIX:ASWN
|
CH |
|
P
|
PICC Property and Casualty Co Ltd
F:PJC
|
CN |
|
C
|
China Southern Airlines Co Ltd
XMUN:ZNHH
|
CN |
|
American States Water Co
NYSE:AWR
|
US |
|
S
|
Smoore International Holdings Ltd
OTC:SMORF
|
CN |
|
S
|
Severn Trent PLC
OTC:STRNY
|
UK |
|
C
|
Commerzbank AG
XHAN:CBK
|
DE |
|
F
|
Fortuna Mining Corp
BMV:FVIN
|
CA |
|
K
|
Knowledge Atlas Technology JSC Ltd
HKEX:2513
|
CN |
Fresenius Medical Care AG
Fresenius Medical Care AG is one of the world’s main kidney care companies. It treats patients with chronic kidney failure by running dialysis clinics and by providing dialysis treatments in hospitals and care centers. It also sells the equipment, filters, and related supplies needed to deliver dialysis, which makes it both a care provider and a medical products supplier. The company makes money in two main ways: from payments for dialysis treatments and from sales of dialysis machines, disposables, and other kidney care products. Its biggest customers are patients who need regular dialysis, along with hospitals, clinics, and healthcare systems that buy its products or contract for treatment services. This gives the business a steady connection to long-term, medically necessary care rather than one-off purchases. What makes the business model distinctive is that it sits on both sides of the dialysis market. Fresenius Medical Care not only treats patients, but also supplies many of the tools used in treatment, so it has direct exposure to the ongoing demand for kidney care from both service fees and product sales. That role gives it deep knowledge of dialysis workflows and a strong position in a specialized part of healthcare.
Fresenius Medical Care AG is one of the world’s main kidney care companies. It treats patients with chronic kidney failure by running dialysis clinics and by providing dialysis treatments in hospitals and care centers. It also sells the equipment, filters, and related supplies needed to deliver dialysis, which makes it both a care provider and a medical products supplier.
The company makes money in two main ways: from payments for dialysis treatments and from sales of dialysis machines, disposables, and other kidney care products. Its biggest customers are patients who need regular dialysis, along with hospitals, clinics, and healthcare systems that buy its products or contract for treatment services. This gives the business a steady connection to long-term, medically necessary care rather than one-off purchases.
What makes the business model distinctive is that it sits on both sides of the dialysis market. Fresenius Medical Care not only treats patients, but also supplies many of the tools used in treatment, so it has direct exposure to the ongoing demand for kidney care from both service fees and product sales. That role gives it deep knowledge of dialysis workflows and a strong position in a specialized part of healthcare.
Profitability: The company said it had another quarter of highly profitable growth, with operating income up 23% and margin expanding again, helped by the FME25+ program and stronger results in Care Delivery and Value-based Care.
U.S. referrals: Management said U.S. same market treatment growth fell 0.9% because of an operational miss in capturing referrals, and now expects full-year U.S. same market treatment growth to be around the Q2 level.
Guidance confirmed: The company confirmed its full-year 2026 outlook, keeping revenue broadly flat and expecting operating income to stay at an elevated level with a mid-single-digit percentage upside/downside range.
TDAPA relief: TDAPA is now expected to be a smaller full-year headwind of around EUR 50 million, better than the earlier expectation of around EUR 100 million, though it will turn into a headwind in the second half.
Buybacks: The first EUR 1 billion share buyback was completed early, and a second EUR 1 billion program has already started, with 2.5 million shares repurchased by quarter-end.
China and costs: Care Enablement in China remained pressured by regulation, while higher raw material and logistics costs tied to Middle East conflict remained a headwind but were still covered within guidance.
HDF rollout: The 5008X and high-volume HDF rollout continued to accelerate, with 227 clinics converted across 23 states by late July and early patient feedback described as encouraging.